487 related articles for article (PubMed ID: 29124482)
1. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
Rocha NA; East C; Zhang J; McCullough PA
Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
[TBL] [Abstract][Full Text] [Related]
2. Volanesorsen: First Global Approval.
Paik J; Duggan S
Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
[TBL] [Abstract][Full Text] [Related]
3. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
Zhang J; Rocha NA; McCullough PA
Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
[TBL] [Abstract][Full Text] [Related]
4. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.
Yang X; Lee SR; Choi YS; Alexander VJ; Digenio A; Yang Q; Miller YI; Witztum JL; Tsimikas S
J Lipid Res; 2016 Apr; 57(4):706-13. PubMed ID: 26848137
[TBL] [Abstract][Full Text] [Related]
5. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
[TBL] [Abstract][Full Text] [Related]
6. Recent Apolipoprotein CIII trials.
Tramontano D; Bini S; D'Erasmo L; Arca M
Curr Opin Lipidol; 2022 Dec; 33(6):309-318. PubMed ID: 36206093
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
[TBL] [Abstract][Full Text] [Related]
8. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Warden BA; Duell PB
Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ApoCIII: the next PCSK9?
Bernelot Moens SJ; van Capelleveen JC; Stroes ES
Curr Opin Lipidol; 2014 Dec; 25(6):418-22. PubMed ID: 25255477
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials.
Fogacci F; Norata GD; Toth PP; Arca M; Cicero AFG
Curr Atheroscler Rep; 2020 May; 22(5):18. PubMed ID: 32458077
[TBL] [Abstract][Full Text] [Related]
11. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
12. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein CIII links dyslipidemia with atherosclerosis.
Kawakami A; Yoshida M
J Atheroscler Thromb; 2009 Mar; 16(1):6-11. PubMed ID: 19262004
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein CIII and diabetes. Is there a link?
Christopoulou E; Tsimihodimos V; Filippatos T; Elisaf M
Diabetes Metab Res Rev; 2019 Mar; 35(3):e3118. PubMed ID: 30557902
[TBL] [Abstract][Full Text] [Related]
15. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease.
Zheng C
Curr Opin Lipidol; 2014 Feb; 25(1):35-9. PubMed ID: 24345989
[TBL] [Abstract][Full Text] [Related]
16. ApoCIII: A multifaceted protein in cardiometabolic disease.
D'Erasmo L; Di Costanzo A; Gallo A; Bruckert E; Arca M
Metabolism; 2020 Dec; 113():154395. PubMed ID: 33058850
[TBL] [Abstract][Full Text] [Related]
17. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R; Viljoen A; Wierzbicki AS
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
[TBL] [Abstract][Full Text] [Related]
19. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
20. Etiology and emerging treatments for familial chylomicronemia syndrome.
Spagnuolo CM; Hegele RA
Expert Rev Endocrinol Metab; 2024 Jul; 19(4):299-306. PubMed ID: 38866702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
